Skip to Content

LadRx Corp LADX

Morningstar Rating
$2.24 +0.11 (5.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LADX is trading within a range we consider fairly valued.
Price
$2.20
Fair Value
$5.14
Uncertainty
Extreme
1-Star Price
$76.52
5-Star Price
$8.25
Economic Moat
Yfpq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LADX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.13
Day Range
$2.242.29
52-Week Range
$0.634.41
Bid/Ask
$2.25 / $2.66
Market Cap
$1.11 Mil
Volume/Avg
409 / 872

Key Statistics

Price/Earnings (Normalized)
0.63
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
22.54%

Company Profile

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
2

Valuation

Metric
LADX
Price/Earnings (Normalized)
0.63
Price/Book Value
3.21
Price/Sales
Price/Cash Flow
0.66
Price/Earnings
LADX

Financial Strength

Metric
LADX
Quick Ratio
1.10
Current Ratio
1.18
Interest Coverage
Quick Ratio
LADX

Profitability

Metric
LADX
Return on Assets (Normalized)
−95.83%
Return on Equity (Normalized)
−880.90%
Return on Invested Capital (Normalized)
−502.06%
Return on Assets
LADX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SdtgyjxntdSrpm$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
JsbfsxhdbZwpfdck$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
CkqlgxprgBfwzny$116.0 Bil
Moderna Inc
MRNA
BkjrjhmgKqndv$51.1 Bil
argenx SE ADR
ARGX
GxnlmgvjhFwgll$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
MvxfxvphJykmb$21.0 Bil
BioNTech SE ADR
BNTX
ZpjxsfqZfsq$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
GgrhsymyDvvjym$15.9 Bil
United Therapeutics Corp
UTHR
FqcftqrtYlxm$14.0 Bil
Incyte Corp
INCY
DwtwrxjlSzpjxjq$12.5 Bil

Sponsor Center